Immobilized SARS-CoV-2 Nucleocapsid Antibody (HC2003), Human Chimeric (Cat. No.?A02039) at 2 μg/mL can bind SARS-CoV-2 Nucleocapsid protein (Cat. No.?Z03488) with a serial dilution.
SARS-CoV-2 Nucleocapsid Antibody (HC2003) conjugated Biotin and Streptavidin-HRP (M00091), are used as a secondary antibody (1 μg/mL, 0.2 μg/mL).
Lane 1: 1μg of SARS-CoV-2 Nucleocapsid protein, reducing(R)
Lane 2: 3μg of SARS-CoV-2 Nucleocapsid protein, reducing(R)
Lane 3: 5μg of SARS-CoV-2 Nucleocapsid protein, reducing(R)
Lane 4: 5μg of SARS-CoV-2 Nucleocapsid protein, non-reducing(NR)
> 90% as analyzed by SDS-PAGE
SARS-CoV-2 Nucleocapsid protein
SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS-CoV-2 Nucleocapsid Protein is associated with nucleic acid. It is the most abundant protein for coronavirus. Because of the strong immunogenicity of coronavirus Nucleocapsid, it is believed that SARS-CoV-2 Nucleocapsid Protein has potential value for the diagnosis of the virus.
| Z03488 | |
|
|
|
| ￥3800 | |
|
|
|
|
|
|
| 聯系我們 | |
